OCT | 2017
FOUNDATION LAUNCHES FOX INSIGHT TO AMPLIFY PATIENT VOICE IN RESEARCH
In collaboration with personal genetics company 23andMe, MJFF announces Fox Insight( foxinsight. org), an online clinical study building a large, diverse research cohort of Parkinson’ s patients and control volunteers. The study’ s goal is to provide researchers, drug makers, regulators and payers critical insight into the lived experience, genetics and variability of Parkinson’ s disease. The study is open to anyone 18 or older worldwide with or without Parkinson’ s disease and aims to recruit tens or even hundreds of thousands of patients to contribute data.
DEC | 2017
LRRK2 TREATMENT ENTERS CLINICAL TESTING
San Francisco biotech Denali Therapeutics announces positive results from its first-in-human LRRK2 clinical trial. The company finds that the experimental treatment is safe, and it lowers LRRK2 protein activity in the blood of volunteers who do not have Parkinson’ s disease. The company also says that it will soon move into studies in people with Parkinson’ s carrying a LRRK2 mutation.
17